Gastroesophageal reflux disease in Naratriptan - how severe and when it was recovered? (a real world drug study)

Summary:

We study how severe was Gastroesophageal reflux disease, when it was recovered, drug effectiveness, race, and more among people who take Naratriptan (naratriptan). This phase IV clinical study is created by eHealthMe based on reports submitted to eHealthMe, and is updated regularly.

What is Naratriptan?

Naratriptan has active ingredients of naratriptan. It is often used in migraine. eHealthMe is studying from 1,481 Naratriptan users. Check the latest studies of Naratriptan.

What is Gastroesophageal reflux disease?

Gastroesophageal reflux disease (a condition in which stomach contents leak backward from the stomach into the oesophagus) is found to be associated with 2,397 drugs and 3,493 conditions by eHealthMe. Check the latest studies of Gastroesophageal reflux disease.



On Jul, 28, 2026

3 people who have Gastroesophageal reflux disease while taking Naratriptan were studied.

Could Naratriptan cause Gastroesophageal reflux disease?

Severity of Gastroesophageal reflux disease *:

  • least: 0.0 %
  • moderate: 100 %
  • severe: 0.0 %
  • most severe: 0.0 %

When people recovered from Gastroesophageal reflux disease *:

  • while on drug: 0.0 %
  • after off the drug: 100 %
  • not yet: 0.0 %

Effectiveness of Naratriptan *:

  • not at all: 0.0 %
  • somewhat: 50 %
  • moderate: 0.0 %
  • high: 50 %
  • very high: 0.0 %

Race of the people *:

  • African American, Non-Hispanic: 0.0 %
  • American Indian/Alaska Native: 0.0 %
  • Asian: 0.0 %
  • Hispanic: 33.33 %
  • Native Hawaiians/Pacific Islanders: 0.0 %
  • Two or more races: 0.0 %
  • White, Non-Hispanic: 66.67 %

Time on Naratriptan *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 33.33 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 33.33 %
  • 5 - 10 years: 33.33 %
  • 10+ years: 0.0 %

Gender of people when taking Naratriptan *:

  • female: 100 %
  • male: 0.0 %

Age of people when taking Naratriptan *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 33.33 %
  • 40-49: 0.0 %
  • 50-59: 33.33 %
  • 60+: 33.33 %

Conditions people have *:

  1. High Blood Cholesterol: 2 people, 66.67%
  2. Stress And Anxiety: 1 person, 33.33%
  3. Allergies: 1 person, 33.33%
  4. Cervicogenic Headache (pain referred to the head from a source in the cervical spine): 1 person, 33.33%
  5. Constipation: 1 person, 33.33%
  6. Diabetes: 1 person, 33.33%
  7. Dry Eyes (lack of adequate tears): 1 person, 33.33%
  8. Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 33.33%
  9. Hypervigilance: 1 person, 33.33%
  10. Restless Leg Syndrome (a powerful urge to move your legs): 1 person, 33.33%

Other drugs people take besides Naratriptan *:

  1. Atorvastatin Calcium: 2 people, 66.67%
  2. Pantoprazole: 2 people, 66.67%
  3. Zyrtec: 1 person, 33.33%
  4. Melatonin: 1 person, 33.33%
  5. Calcium: 1 person, 33.33%
  6. Claritin: 1 person, 33.33%
  7. Clonazepam: 1 person, 33.33%
  8. Cymbalta: 1 person, 33.33%
  9. Famotidine: 1 person, 33.33%
  10. Flaxseed Oil: 1 person, 33.33%

Other side effects people have besides Gastroesophageal reflux disease *:

  1. Stress And Anxiety: 1 person, 33.33%
  2. Raynaud's Phenomenon (discoloration of the fingers, toes, and occasionally other areas): 1 person, 33.33%
  3. Osteoporosis (bones weak and more likely to break): 1 person, 33.33%
  4. Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 33.33%
  5. Insomnia (sleeplessness): 1 person, 33.33%
  6. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 33.33%
  7. Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 33.33%
  8. End-Stage Kidney Disease (End stage renal disease (ESRD) is the last stage (stage five) of chronic kidney disease (CKD). It occurs when the kidneys are no longer able to work at a level needed for day-to-day life): 1 person, 33.33%
  9. Diabetes: 1 person, 33.33%
  10. Coronary Artery Spasm: 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Naratriptan and have Gastroesophageal reflux disease?

Check whether Gastroesophageal reflux disease is associated with a drug or a condition

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

How the study uses the data?

The study is based on naratriptan (the active ingredients of Naratriptan). Other drugs that have the same active ingredients (e.g. generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: